Boehringer Bemoans Medicare Drug Price Talks As 'A Sham'
Boehringer Ingelheim Pharmaceuticals Inc. slammed the new Medicare drug price negotiation program in a Connecticut federal court filing as a "sham from beginning to end," even as it indicated Thursday that...To view the full article, register now.
Already a subscriber? Click here to view full article